Online inquiry

IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11832MR)

This product GTTS-WQ11832MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11832MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10210MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ7970MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ9346MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ13109MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ10062MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ13044MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ14036MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ2707MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW